查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2024914

流感疫苗市場規模、佔有率和趨勢：按疫苗類型、技術、年齡層、給藥途徑、地區分類，並預測至 2026-2034 年。

Influenza Vaccine Market Size, Share, and Trends by Vaccine Type, Technology, Age Group, Route of Administration, Region, and Forecast 2026-2034
出版日期: | 出版商: IMARC | 英文 135 Pages | 商品交期: 2-3個工作天內

價格

2025年全球流感疫苗市場規模為76億美元。展望未來，IMARC Group預測，該市場將以6.14%的複合年成長率從2026年成長至2034年，到2034年達到133億美元。目前，北美市場佔據主導地位，預計2025年將佔據超過53.4%的市場。推動流感疫苗市場成長的關鍵因素包括：政府機構為支持疫苗接種計畫而採取的多項積極措施、流感病例和季節性疫情的增加，以及更有效、預防範圍更廣的流感疫苗的出現。

全球流感疫苗市場正因人們對季節性流感的認知不斷提高以及醫療保健支出不斷成長等因素而持續成長。老年人口的增加，尤其是老年人更容易出現流感併發症，也是推動市場成長的另一個重要因素。世界各國政府都在加大疫苗接種計劃的投入，這對市場成長產生了正面影響。新冠肺炎疫情凸顯了預防醫學的重要性，許多人開始意識到預防勝於治療，從而提高了流感疫苗的接種率。 mRNA疫苗等新型研發方法正在提升疫苗的安全性和有效性。此外，流感病毒株數量的增加以及每年接種疫苗的需求也確保了疫苗的持續需求。醫療設施的增加，尤其是在開發中國家，預計將進一步提高疫苗的可及性和接受度。

美國正崛起為流感疫苗的主要區域市場。截至2024年11月，美國已分發了1.3419億劑2024-2025流感季的流感疫苗。美國的疫苗供應主要依賴私營生產商，預計本流感季的總供應量為1.48億劑。供應量的成長反映了美國市場對流感疫苗日益成長的需求，這主要是由於需要預防季節性流感爆發，尤其是在老年人和慢性病患者等高風險族群中。在四價疫苗和mRNA疫苗等疫苗技術創新以及政府免疫計畫的支持下，美國流感疫苗市場持續擴張。隨著疫苗的可及性和有效性不斷提高，生產商正在積極響應預計的需求成長，市場預計將繼續成長。

流感疫苗市場趨勢：

季節性流感爆發與大流行病的興起

季節性流感病例的增加導致住院率上升。例如，2022-2023流感季，美國報告了3,100萬例流感病例。此外，2021-2022流感季，有4977人死於流感。而且，美國很大一部分人口未接種疫苗。此外，2021-2022流感季，18至49歲族群的流感疫苗接種率僅37%，遠低於兒童及老年人的接種率。因此，醫療機構日益重視流感疫苗接種的重要性，推動了市場成長。例如，世界衛生組織（世衛組織）於2023年2月發布了關於2023-2024流感季流感疫苗病毒株組成的建議。該消息是在為期四天的流感疫苗株組成會議結束時舉行的新聞發布會上宣布的。

人們對流感疫苗接種的認知不斷提高

季節性流感的蔓延是推動市場成長的主要因素。例如，根據2022年2月發布的全球流感數據，估計全球約有10億人感染了季節性流感。報告也指出，在這10億人中，每年約有300萬至500萬人發展為重症流感。此外，根據世界衛生組織2022年12月發布的數據，歐洲地區有5%至15%的人口受到流感影響。同樣，2021年7月發表在《PLOS One》期刊上的報導指出，每年新增流感病例中，約5%至10%發生在兒童，20%至30%發生在成人。流感病毒感染人數的增加提高了人們對流感疫苗接種的認知，這為整體市場成長帶來了良好的前景。此外，醫療機構正在進行宣傳活動，普及接種疫苗的益處，也推動了對流感疫苗的需求。例如，賽諾菲在2022年6月進行的一項醫療保健調查報告顯示，藥劑師和醫生正向美國疾病管制與預防中心（CDC）建議為65歲及以上的老年人提供「全區高劑量四價流感疫苗」等疫苗。這一在所有年齡層中不斷成長的趨勢將在預測期內持續推動流感疫苗市場佔有率的成長。

擴大政府機構的支持

全球各國政府機構正與領導企業合作，加速流感疫苗的研發。根據流感疫苗市場統計數據顯示，2021年9月，美國疾病管制與預防中心（CDC）加入了由生物醫學高級研究與發展局（BARDA）主導的跨機構夥伴關係，旨在資助新型流感疫苗的研發。此外，各國政府機構正在簡化和完善核准流程，這也有助於擴大流感疫苗市場需求。例如，2022年7月，美國食品藥物管理局（FDA）核准了GlaxoSmithKline Plc四價流感疫苗「Fluarix」的核准申請。因此，各國政府正在加大對流感疫苗臨床試驗和研發的投入。例如，2022年3月，澳洲政府斥資超過1億美元用於高風險族群的季節性流感疫苗接種。此外，大型醫療保健公司正在大力投資疫苗領域的創新和先進治療方法，這也對流感疫苗市場的前景產生了積極影響。

目錄

第1章：序言

第2章：調查方法

  • 調查目的
  • 相關利益者
  • 數據來源
    • 主要訊息
    • 次要訊息
  • 市場估值
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第3章執行摘要

第4章：引言

第5章：全球流感疫苗市場

  • 市場概覽
  • 市場表現
  • 新冠疫情的影響
  • 市場預測

第6章 市場區隔：依疫苗類型分類

  • 四價
  • 三價

第7章 市場區隔：依技術分類

  • 蛋
  • 基於細胞

第8章 市場區隔：依年齡層別分類

  • 兒童
  • 成人

第9章 市場區隔：依給藥途徑

  • 注射
  • 鼻噴霧

第10章 市場區隔：依地區分類

  • 北美洲
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲

第11章 SWOT 分析

第12章：價值鏈分析

第13章：波特五力分析

第14章：價格分析

第15章 競爭格局

  • 市場結構
  • 大公司
  • 主要公司簡介
    • Abbott Laboratories
    • AstraZeneca plc
    • CSL Limited
    • Daiichi Sankyo Company Limited
    • Emergent BioSolutions Inc.
    • F. Hoffmann-La Roche AG
    • Gamma Vaccines Pty Ltd
    • GlaxoSmithKline plc
    • Merck & Co. Inc.
    • Novartis AG
    • Pfizer Inc.
    • Sanofi
    • SINOVAC
Product Code: SR112026A4206

The global influenza vaccine market size was valued at USD 7.6 Billion in 2025. Looking forward, IMARC Group estimates the market to reach USD 13.3 Billion by 2034, exhibiting a CAGR of 6.14% from 2026-2034. North America currently dominates the market, holding a market share of over 53.4% in 2025. Some of the key factors supporting the influenza vaccine market growth include the launch of many positive initiatives by government bodies to support vaccination programs, increasing cases of influenza and seasonal outbreaks, and more effective and broadly protective influenza vaccines.

The global influenza vaccine market is witnessing growth on account of several factors, factors such as rising awareness regarding the seasonal flu and increasing healthcare spending. The increasing elderly population who are more prone to complications arising from flu infections is also another driving factor. Governments worldwide are channeling resources into vaccination programs. This in turn contributes positively toward the growth of the market. The COVID-19 pandemic reinforced the rationale for preventive medicine, thus increasing the uptake of flu vaccines, as many people began to understand the importance of prevention over treatment. With new ways of developing vaccines such as mRNA-based vaccines, safety, and efficiency of vaccines have improved. Moreover, due to the rising number of influenza strains, and the requirement that individuals be vaccinated every year, there is perpetual demand. The rise of health care facilities particularly in developing countries is likely to increase further the usage and acceptance of vaccines.

The United States has emerged as a key regional market for influenza vaccines. As of November 2024, the US has distributed 134.19 million doses of the flu vaccine for the 2024-25 season. Vaccine supply in the U.S. largely depends on private manufacturers, with projections for a total of 148 million doses of influenza vaccine for the current season. This increasing supply reflects the growing demand within the influenza vaccine market in the U.S. market, driven by the need to prevent seasonal outbreaks, particularly among high-risk populations such as the elderly and those with chronic conditions. The influenza vaccine market in the U.S. continues to expand, bolstered by innovations in vaccine technology, such as quadrivalent and mRNA vaccines, and supported by government vaccination programs. With ongoing improvements in vaccine accessibility and efficacy, manufacturers are responding to higher demand projections, positioning the market for continued growth.

INFLUENZA VACCINE MARKET TRENDS:

INCREASING SEASONAL INFLUENZA OUTBREAKS AND PANDEMICS

The rising cases of seasonal influenza are elevating the hospitalization rates. For example, there were 31 million cases of influenza in the United States during the 2022-2023 flu season. Moreover, there were 4,977 number of deaths caused by influenza during the 2021-2022 flu season. In addition to this, a large part of the population in the United States failed to get vaccinated. Additionally, in 2021-2022, only 37% of those aged 18 to 49 years received a flu vaccination, which was much lower as compared to children and the elderly. As such, the elevating focus among healthcare organizations on highlighting the importance of influenza vaccinations is bolstering the market growth. For instance, in February 2023, the World Health Organization (WHO) announced the recommendations for the viral composition of influenza vaccines for the 2023-2024 influenza season. The announcement was made at an information session at the end of a 4-day meeting on the composition of influenza virus vaccines.

THE RISING AWARENESS TOWARDS INFLUENZA VACCINATION

The growing prevalence of seasonal influenza is primarily bolstering the market growth. For example, the global flu data that was published in February 2022 mentioned that an estimated 1 billion individuals worldwide were infected by seasonal influenza. In line with this, the report also stated that out of those 1 billion, about 3 to 5 million people had a severe case of flu every year. Furthermore, according to the data published by WHO in December 2022, 5%-15% of the population was affected by influenza in the European region. Similarly, the Plos One Journal article published in July 2021 mentioned that approximately 5%-10% and 20%-30% of new cases of influenza infections occurred among children and adults annually. The elevating cases of the influenza virus are increasing awareness among individuals towards influenza vaccination, which is providing a positive outlook to the overall market growth. Besides this, healthcare organizations are launching campaigns to provide information regarding the benefits of immunization, thereby driving the demand for influenza vaccines. For example, a healthcare survey conducted in June 2022 by Sanofi reported that pharmacists and physicians recommended Centers for Disease Control and Prevention (CDC) to provide vaccines like Fluzone high dose quadrivalent, for people who're 65 and older, for the treatment of influenza. The growing inclination among individuals of all age groups will continue to propel the influenza vaccine market share over the forecasted period.

THE GROWING SUPPORT FROM GOVERNMENT BODIES

Government agencies around the world are partnering with leading companies to facilitate R&D work in the development of influenza vaccines. According to the statistics of the influenza vaccine market, in September 2021, the Centers for Disease Control and Prevention (CDC) joined a broad interagency partnership led by the Biomedical Advanced Research and Development Authority (BARDA) that funded the advanced development of new influenza vaccines. In addition, government bodies are streamlining and upgrading the procedure of license approvals, which is contributing to the growth in demand in the flu vaccine market. For instance, in July 2022, the U.S. FDA sanctioned the appeal from GlaxoSmithKline for the license Fluarix, which is a quadrivalent flu vaccine. To this effect, the government is spending on clinical trials and R&D work on the development of flu vaccines. For example, during March 2022, Australia's governmental entities spent more than USD 100 Million for seasonal influenza vaccination against individuals under high risk. In addition to this, giant health-care corporations are significantly investing in the release of innovative advanced therapies in terms of vaccines, thus also influencing positively in the case of the influenza vaccine market outlook.

INFLUENZA VACCINE INDUSTRY SEGMENTATION:

ANALYSIS BY VACCINE TYPE:

  • Quadrivalent
  • Trivalent

Quadrivalent stands as the largest vaccine type in 2025, holding over 69% of the market. Quadrivalent influenza vaccines are specifically designed to protect against four flu viruses, namely two influenza A viruses and two influenza B viruses. The quadrivalent segment holds a significant share of the influenza vaccine market, owing to its efficacy against viral infections, cost-effectiveness, and easy availability in clinics and hospitals. In addition to this, the fast product approvals for the quadrivalent type of vaccine are also fueling the market growth. For example, in July 2022, the United States FDA approved the request of GlaxoSmithKline for the Fluarix, which is a quadrivalent vaccine. The Fluarix quadrivalent vaccine provides active immunization to prevent disease caused by the influenza A subtype virus and type B virus. Furthermore, key companies are investing in vaccine facilities to elevate the production processes, thereby driving the global market for influenza vaccine. For example, in April 2021, Sanofi invested over € 600 million to build a new vaccine facility in Toronto to increase its supply of influenza vaccines in the United States, Canada, and Europe. The new facility developed quadrivalent influenza vaccines and served its customers with effective vaccinations.

ANALYSIS BY TECHNOLOGY:

  • Egg-based
  • Cell-based

Egg-based leads the market with around 69% of market share in 2025. Egg-based technology refers to one of the conventional methods utilized for vaccine production, wherein the influenza virus strains are grown in chicken eggs before being processed and harvested for vaccine formulation. Moreover, the egg-based method has been extensively adopted, owing to its established safety, scalability, cost-effectiveness, etc. For example, in February 2024, the WHO announced recommendations for the viral composition of influenza vaccines for the 2024-2025 influenza season in the northern hemisphere. The egg-based vaccines that are recommended include an A/Victoria/4897/2022 (H1N1) pdm09-like virus, an A/Thailand/8/2022 (H3N2)-like virus, and a B/Austria/1359417/2021 (B/Victoria lineage)-like virus.

ANALYSIS BY AGE GROUP:

  • Pediatric
  • Adult

Pediatric leads the market with over 72% of market share in 2025. Pediatric vaccines are specifically formulated to enhance the immune systems of children, especially those under the age of five, who are more susceptible to severe flu-related complications. These vaccinations aid in ensuring adequate protection against the disease. Consequently, healthcare providers, government bodies, and parents are recognizing the importance of pediatric influenza vaccination, leading to the escalating demand for pediatric flu vaccines.

ANALYSIS BY ROUTE OF ADMINISTRATION:

  • Injection
  • Nasal Spray

The injection segment remains widely used, particularly intramuscular injections. This segment is expected to grow rapidly due to advancements in injection technologies, such as the development of microneedle patches that aim to simplify administration and improve patient compliance.

On the other hand, nasal spray influenza vaccines provide a needle-free alternative to traditional injections, delivering the vaccine via the nasal mucosa to stimulate a mucosal immune response. Though less common than injectable vaccines, nasal spray options are increasingly favored by individuals, especially children, who may have a fear of needles. The segment is seeing growth due to ongoing research aimed at improving formulations, expanding eligibility to a broader age range, and refining the delivery technology.

BREAKUP BY REGION:

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

In 2025, North America accounted for the largest market share of over 53%. In North America, the growing prevalence of the influenza virus is propelling the regional market. According to the CDC data, nearly 150,865 influenza-positive cases were reported in December 2022, among which 149,704 cases were influenza A and 1,61 influenza B virus types. In line with this, in December 2022, the Public Health Agency of Canada mentioned that nearly 34,413 influenza cases were reported in Canada from August 2022 to December 2022. Such increased occurrence of influenza cases among the population across North America is expected to drive the need for influenza vaccines. For instance, in June 2021, NIH launched the clinical trials of FluMos-v1, a vaccine candidate in the United States. This vaccine stimulates antibodies against multiple influenza virus strains by displaying part of the influenza virus proteins

KEY REGIONAL TAKEAWAYS:

UNITED STATES INFLUENZA VACCINE MARKET ANALYSIS

In 2025, the Unites States accounts for over 70% of the influenza vaccine market in North America. Strong government initiatives, a strong healthcare system, and an aging population are the main factors propelling the industry. Increasing vaccine uptake is largely dependent on the Centers for Disease Control and Prevention's (CDC) annual vaccination efforts. Between 9 and 45 million influenza cases are estimated to occur in the United States each year, according to the CDC, with related hospitalizations and deaths underscoring the importance of prevention. For vulnerable populations, including the elderly, small children, pregnant women, and people with long-term medical issues, influenza vaccination is strongly advised. Interestingly, more than 16% of Americans are 65 years of age or older, a demographic that has far greater influenza complications and is therefore a prime target for vaccination campaigns.

Additionally, technological developments have fueled market expansion. The effectiveness and coverage of vaccines have increased since the advent of quadrivalent vaccines, which offer protection against four influenza strains. The drawbacks of conventional egg-based vaccinations have been overcome by cell-based and recombinant technologies, which shorten production times and increase scalability during epidemics. Innovations like mRNA-based flu vaccines, which promise increased efficacy and quick adaptation to new strains, are the result of pharmaceutical companies like Sanofi, GlaxoSmithKline, and Moderna investing more in research and development. The industry is further supported by public-private collaborations, such as those made possible by the Biomedical Advanced Research and Development Authority (BARDA). Furthermore, a wider population may now get vaccines because to employer-sponsored immunization programs, pharmacy flu clinics, and growing awareness campaigns. The market for influenza vaccines in the US is expected to expand steadily due to this combination of reasons.

EUROPE INFLUENZA VACCINE MARKET ANALYSIS

Adoption of influenza vaccines in Europe is being driven by aging populations, universal healthcare systems, and strict government regulations. Free flu vaccination programs have been put in place in nations including the UK, Germany, and France for vulnerable populations, such as the elderly and children. The demand is being driven by the European Centre for Disease Prevention and Control (ECDC), which places emphasis on reaching a 75% immunization target in high-risk populations. The necessity of vaccination has been further highlighted by the rise in comorbidities such as diabetes and cardiovascular disorders, which exacerbate flu-related consequences. With large expenditures in vaccine production facilities, Europe's emphasis on pandemic preparedness also boosts the industry. Large-scale awareness campaigns and school-based immunization programs that target younger populations boost the industry. The growth of mRNA-based flu vaccines in Europe is another emerging driver, offering improved efficacy and rapid production cycles.

ASIA PACIFIC INFLUENZA VACCINE MARKET ANALYSIS

Large-scale government vaccination initiatives, growing public awareness, and rising healthcare costs all contribute to the market's growth. Leading nations include China, South Korea, and Japan, with Japan attaining yearly immunization rates of more than 50% among its senior citizens. Due to the great potential for influenza transmission, widespread vaccination campaigns are required in densely populated nations like China and India. To increase vaccine access, especially in remote areas, governments are spending money on distribution networks and cold chain infrastructure. Rapid urbanization in emerging nations increases vulnerability to influenza outbreaks and raises demand for vaccines. Furthermore, partnerships between regional producers and international pharmaceutical firms are stimulating innovation, and current clinical studies for next-generation vaccines-like those based on mRNA and intranasal formulations-are expected to propel further expansion.

LATIN AMERICA INFLUENZA VACCINE MARKET ANALYSIS

The growing prevalence of seasonal flu and the government's increased emphasis on public health are driving the influenza vaccination industry in Latin America. Brazil and Mexico are important markets because of their sizable populations and pro-immunization laws. Through national immunization programs, governments frequently give away free vaccines to vulnerable populations, like children and the elderly. According to a report by International Federation on Ageing, Brazil has one of the highest rates of influenza vaccination worldwide among older persons (98.2%) and people with long-term illnesses (86.3%) in 2019. The robust government-led influenza vaccination effort, which depends on both in-person and remote mobilization, is primarily responsible for the target populations' compliance.

MIDDLE EAST AND AFRICA INFLUENZA VACCINE MARKET ANALYSIS

Growing government initiatives, foreign aid, and growing awareness of preventative healthcare are the main factors propelling the market. To avoid widespread epidemics, nations like Saudi Arabia and the United Arab Emirates have made flu vaccination a priority, especially for pilgrims traveling for events like the Hajj. Accessibility is increased by the WHO's Global Influenza Strategy, which funds immunization campaigns in low- and middle-income African nations. Uptake of the influenza vaccine is increasing in South Africa, where yearly immunization campaigns target vulnerable populations and healthcare staff. Partnerships with international health groups to improve vaccine distribution and awareness are helping to mitigate issues like the lack of adequate healthcare facilities in some areas.

COMPETITIVE LANDSCAPE:

Key players in the influenza vaccine market are significantly driving the market growth through strategic initiatives. These companies are focusing on enhancing vaccine efficacy with advanced technologies like quadrivalent and mRNA-based vaccines, expanding accessibility through partnerships with governments and healthcare providers, and engaging in extensive research and development. Manufacturers are also responding to rising demand by improving vaccine production capacity, with companies like Moderna and AstraZeneca exploring new formulations and delivery methods, such as microneedle patches, to increase patient compliance. Furthermore, these key players are involved in global vaccine distribution, ensuring greater reach and contributing to the overall market expansion.

The report provides a comprehensive analysis of the competitive landscape in the influenza vaccine market with detailed profiles of all major companies, including:

  • Abbott Laboratories
  • AstraZeneca plc
  • CSL Limited
  • Daiichi Sankyo Company Limited
  • Emergent BioSolutions Inc.
  • F. Hoffmann-La Roche AG
  • Gamma Vaccines Pty Ltd
  • GlaxoSmithKline plc
  • Merck & Co. Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi
  • SINOVAC

KEY QUESTIONS ANSWERED IN THIS REPORT

1. What is influenza vaccine?

2. How big is the influenza vaccine market?

3. What is the expected growth rate of the global influenza vaccine market during 2026-2034?

4. What are the key factors driving the global influenza vaccine market?

5. What is the leading segment of the global influenza vaccine market based on the vaccine type?

6. What is the leading segment of the global influenza vaccine market based on technology?

7. What is the leading segment of the global influenza vaccine market based on age group?

8. What are the key regions in the global influenza vaccine market?

9. Who are the key players/companies in the global influenza vaccine market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Influenza Vaccine Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Vaccine Type

  • 6.1 Quadrivalent
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Trivalent
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast

7 Market Breakup by Technology

  • 7.1 Egg-based
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Cell-based
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast

8 Market Breakup by Age Group

  • 8.1 Pediatric
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Adult
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast

9 Market Breakup by Route of Administration

  • 9.1 Injection
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Nasal Spray
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia-Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 Abbott Laboratories
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
      • 15.3.1.3 Financials
      • 15.3.1.4 SWOT Analysis
    • 15.3.2 AstraZeneca plc
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
      • 15.3.2.3 Financials
      • 15.3.2.4 SWOT Analysis
    • 15.3.3 CSL Limited
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
      • 15.3.3.3 Financials
      • 15.3.3.4 SWOT Analysis
    • 15.3.4 Daiichi Sankyo Company Limited
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
      • 15.3.4.3 Financials
      • 15.3.4.4 SWOT Analysis
    • 15.3.5 Emergent BioSolutions Inc.
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
      • 15.3.5.3 Financials
      • 15.3.5.4 SWOT Analysis
    • 15.3.6 F. Hoffmann-La Roche AG
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
      • 15.3.6.3 SWOT Analysis
    • 15.3.7 Gamma Vaccines Pty Ltd
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
    • 15.3.8 GlaxoSmithKline plc
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
      • 15.3.8.3 Financials
      • 15.3.8.4 SWOT Analysis
    • 15.3.9 Merck & Co. Inc.
      • 15.3.9.1 Company Overview
      • 15.3.9.2 Product Portfolio
      • 15.3.9.3 Financials
      • 15.3.9.4 SWOT Analysis
    • 15.3.10 Novartis AG
      • 15.3.10.1 Company Overview
      • 15.3.10.2 Product Portfolio
      • 15.3.10.3 Financials
      • 15.3.10.4 SWOT Analysis
    • 15.3.11 Pfizer Inc.
      • 15.3.11.1 Company Overview
      • 15.3.11.2 Product Portfolio
      • 15.3.11.3 Financials
      • 15.3.11.4 SWOT Analysis
    • 15.3.12 Sanofi
      • 15.3.12.1 Company Overview
      • 15.3.12.2 Product Portfolio
      • 15.3.12.3 Financials
      • 15.3.12.4 SWOT Analysis
    • 15.3.13 SINOVAC
      • 15.3.13.1 Company Overview
      • 15.3.13.2 Product Portfolio
      • 15.3.13.3 Financials

List of Figures

  • Figure 1: Global: Influenza Vaccine Market: Major Drivers and Challenges
  • Figure 2: Global: Influenza Vaccine Market: Sales Value (in Billion USD), 2020-2025
  • Figure 3: Global: Influenza Vaccine Market Forecast: Sales Value (in Billion USD), 2026-2034
  • Figure 4: Global: Influenza Vaccine Market: Breakup by Vaccine Type (in %), 2025
  • Figure 5: Global: Influenza Vaccine Market: Breakup by Technology (in %), 2025
  • Figure 6: Global: Influenza Vaccine Market: Breakup by Age Group (in %), 2025
  • Figure 7: Global: Influenza Vaccine Market: Breakup by Route of Administration (in %), 2025
  • Figure 8: Global: Influenza Vaccine Market: Breakup by Region (in %), 2025
  • Figure 9: Global: Influenza Vaccine (Quadrivalent) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 10: Global: Influenza Vaccine (Quadrivalent) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 11: Global: Influenza Vaccine (Trivalent) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 12: Global: Influenza Vaccine (Trivalent) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 13: Global: Influenza Vaccine (Egg-based) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 14: Global: Influenza Vaccine (Egg-based) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 15: Global: Influenza Vaccine (Cell-based) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 16: Global: Influenza Vaccine (Cell-based) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 17: Global: Influenza Vaccine (Pediatric) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 18: Global: Influenza Vaccine (Pediatric) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 19: Global: Influenza Vaccine (Adult) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 20: Global: Influenza Vaccine (Adult) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 21: Global: Influenza Vaccine (Injection) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 22: Global: Influenza Vaccine (Injection) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 23: Global: Influenza Vaccine (Nasal Spray) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 24: Global: Influenza Vaccine (Nasal Spray) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 25: North America: Influenza Vaccine Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 26: North America: Influenza Vaccine Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 27: United States: Influenza Vaccine Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 28: United States: Influenza Vaccine Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 29: Canada: Influenza Vaccine Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 30: Canada: Influenza Vaccine Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 31: Asia-Pacific: Influenza Vaccine Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 32: Asia-Pacific: Influenza Vaccine Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 33: China: Influenza Vaccine Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 34: China: Influenza Vaccine Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 35: Japan: Influenza Vaccine Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 36: Japan: Influenza Vaccine Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 37: India: Influenza Vaccine Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 38: India: Influenza Vaccine Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 39: South Korea: Influenza Vaccine Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 40: South Korea: Influenza Vaccine Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 41: Australia: Influenza Vaccine Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 42: Australia: Influenza Vaccine Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 43: Indonesia: Influenza Vaccine Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 44: Indonesia: Influenza Vaccine Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 45: Others: Influenza Vaccine Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 46: Others: Influenza Vaccine Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 47: Europe: Influenza Vaccine Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 48: Europe: Influenza Vaccine Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 49: Germany: Influenza Vaccine Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 50: Germany: Influenza Vaccine Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 51: France: Influenza Vaccine Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 52: France: Influenza Vaccine Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 53: United Kingdom: Influenza Vaccine Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 54: United Kingdom: Influenza Vaccine Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 55: Italy: Influenza Vaccine Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 56: Italy: Influenza Vaccine Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 57: Spain: Influenza Vaccine Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 58: Spain: Influenza Vaccine Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 59: Russia: Influenza Vaccine Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 60: Russia: Influenza Vaccine Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 61: Others: Influenza Vaccine Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 62: Others: Influenza Vaccine Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 63: Latin America: Influenza Vaccine Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 64: Latin America: Influenza Vaccine Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 65: Brazil: Influenza Vaccine Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 66: Brazil: Influenza Vaccine Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 67: Mexico: Influenza Vaccine Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 68: Mexico: Influenza Vaccine Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 69: Others: Influenza Vaccine Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 70: Others: Influenza Vaccine Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 71: Middle East and Africa: Influenza Vaccine Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 72: Middle East and Africa: Influenza Vaccine Market: Breakup by Country (in %), 2025
  • Figure 73: Middle East and Africa: Influenza Vaccine Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 74: Global: Influenza Vaccine Industry: SWOT Analysis
  • Figure 75: Global: Influenza Vaccine Industry: Value Chain Analysis
  • Figure 76: Global: Influenza Vaccine Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Influenza Vaccine Market: Key Industry Highlights, 2025 and 2034
  • Table 2: Global: Influenza Vaccine Market Forecast: Breakup by Vaccine Type (in Million USD), 2026-2034
  • Table 3: Global: Influenza Vaccine Market Forecast: Breakup by Technology (in Million USD), 2026-2034
  • Table 4: Global: Influenza Vaccine Market Forecast: Breakup by Age Group (in Million USD), 2026-2034
  • Table 5: Global: Influenza Vaccine Market Forecast: Breakup by Route of Administration (in Million USD), 2026-2034
  • Table 6: Global: Influenza Vaccine Market Forecast: Breakup by Region (in Million USD), 2026-2034
  • Table 7: Global: Influenza Vaccine Market: Competitive Structure
  • Table 8: Global: Influenza Vaccine Market: Key Players